{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:11:51Z","timestamp":1767967911289,"version":"3.49.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,12]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Bone marrow fibrosis may be a late reversible toxicity of high-dose imatinib therapy in chronic myeloid leukemia.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018027516","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T16:54:11Z","timestamp":1549385651000},"page":"370-374","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"first","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"},{"name":"Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia;"},{"name":"Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia;"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[{"name":"Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia;"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"},{"name":"Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia; and"},{"name":"School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"},{"name":"Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia;"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devendra","family":"Hiwase","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia;"},{"name":"Department of Haematology and"},{"name":"Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia;"},{"name":"School of Medicine, University of Adelaide, Adelaide, SA, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,2,5]]},"reference":[{"issue":"11","key":"2020021108335872100_B1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021108335872100_B2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study","volume":"99","author":"Baccarani","year":"2014","journal-title":"Int J Hematol"},{"issue":"24","key":"2020021108335872100_B3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2020021108335872100_B4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021108335872100_B5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"2020021108335872100_B6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"2020021108335872100_B7","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020021108335872100_B8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"2020021108335872100_B9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"2020021108335872100_B10","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1038\/sj.leu.2403172","article-title":"Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial","volume":"17","author":"Buesche","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"2020021108335872100_B11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2020021108335872100_B12","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.3324\/haematol.2014.117028","article-title":"Inhibition of c-Kit by tyrosine kinase inhibitors","volume":"100","author":"Galanis","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"2020021108335872100_B13","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","article-title":"Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"108","author":"Kovitz","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2020021108335872100_B14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/10428190500097581","article-title":"The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy","volume":"46","author":"Kantarjian","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2020021108335872100_B15","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1038\/sj.leu.2404917","article-title":"Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia","volume":"21","author":"Buesche","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"2020021108335872100_B16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.20380","article-title":"Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia","volume":"101","author":"Bueso-Ramos","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"2020021108335872100_B17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"3","key":"2020021108335872100_B18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2010.11.035","article-title":"Inhibition of PDGF, TGF-\u03b2, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist nilotinib","volume":"55","author":"Liu","year":"2011","journal-title":"J Hepatol"},{"issue":"7","key":"2020021108335872100_B19","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"issue":"11","key":"2020021108335872100_B20","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin Ther"},{"issue":"5","key":"2020021108335872100_B21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/3\/370\/1631048\/advances027516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/3\/370\/1631048\/advances027516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:03:45Z","timestamp":1581411825000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/3\/370\/246787\/Bone-marrow-fibrosis-associated-with-longterm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018027516","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,5]]}}}